Elantan LA 25 mg Prolonged Release Capsules
*Company:
MERUS LabsStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 16 September 2025
File name
ie-pil-ela-la-25-en.pdf
Reasons for updating
- XPIL Updated
Free text change information supplied by the pharmaceutical company
The database is currently being updated to incorporate the XPIL for all relevant products.
Updated on 29 November 2023
File name
ie-pil-ela-la-25-en.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - driving and using machines
- Change to section 3 - use in children/adolescents
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 29 November 2023
File name
ie-pil-ela-la-25-en.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - driving and using machines
- Change to section 3 - use in children/adolescents
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 30 March 2023
File name
ie-pil-ela-la-25-en_clean.pdf
Reasons for updating
- Change to section 6 - date of revision
- Change to date of revision
Updated on 12 January 2023
File name
ie-smpc-ela-la-25-en-clean.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.8 - Undesirable effects
- Change to section 6.1 - List of excipients
- Change to section 6.5 - Nature and contents of container
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 12 January 2023
File name
ie-pil-ela-la-25-en-clean.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 30 August 2022
File name
ie-pil-ela-la-25-en.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 30 August 2022
File name
ie-smpc-ela-la-25-en.pdf
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 25 November 2019
File name
ie-smpc-ela-en.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 25 November 2019
File name
ie-pil-ela-en.pdf
Reasons for updating
- New PIL for new product
MERUS Labs
Address:
Merus Labs Luxco II S.à.R.L. 208, Val des Bons Malades L-2121 Luxembourg LuxembourgMedical Information E-mail:
medinfo@norgine.comMedical Information Direct Line:
+44 (0)1895 8266606Customer Care direct line:
+31205670954Stock Availability:
UKIsupport@norgine.com.